Oligodendrocyte Dysfunction Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), responsible for ensheathing axons with a multilamellar lipid-rich membrane that enables rapid saltatory conduction. In neurodegenerative diseases, oligodendrocyte dysfunction and demyelination contribute significantly to disease progression through axonal energy failure, metabolic compromise, and loss of trophic support. This pathway examines oligodendrocyte biology, mechanisms of dysfunction, and their role in Alzheimer's disease, Parkinson's disease, ALS, and related disorders.
Oligodendrocyte lineage progression:
{{mermaid}}
flowchart TD
A[Neural Stem Cell] --> B[Oligodendrocyte Precursor Cell OPC]
B --> C[Pre-Oligodendrocyte]
C --> D[Mature Oligodendrocyte]
E[PDGF-A] --> B
F[SHH](/genes/shh) --> B
G[FGF2](/genes/fgf2) --> B
H[CNTF](/genes/cntf) --> D
I[NT-3] --> D
J[OLIG2](/genes/olig2) --> B
K[NKX2.2] --> C
L[SOX10](/genes/sox10) --> D
M[MBP](/genes/mbp) --> D
{{/mermaid}}
| Component | Function |
|---|---|
| Myelin Basic Protein (MBP) | Structural integrity, compaction |
| Proteolipid Protein (PLP) | Membrane stability |
| Myelin Oligodendrocyte Glycoprotein (MOG) | Surface recognition |
| Oligodendrocyte-Specific Protein (OSP/claudin-11) | Tight junctions |
| Galactocerebroside (GalC) | Surface antigen |
Amyloid Effects
Tau Pathology
Metabolic Compromise
Dopaminergic Axon Vulnerability
Alpha-Synuclein Effects
Primary Oligodendropathy
OPC Dysfunction
{{mermaid}}
flowchart TD
A[Toxic Stimuli] --> B[Aβ, α-syn, Oxidative Stress]
B --> C[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
C --> D[ATP Depletion]
D --> E[Failure of Myelin Maintenance]
E --> F[Oligodendrocyte Death]
B --> G[Calcium Dysregulation]
G --> H[ER Stress]
H --> F
B --> I[Inflammation]
I --> J[Microglial Activation]
J --> K[TNF-α, IL-1β Cytotoxicity]
K --> F
L[Excitotoxicity](/entities/excitotoxicity) --> M[AMPA/Kainate Receptor Overactivation]
M --> G
M --> C
{{/mermaid}}
| Approach | Target | Status |
|---|---|---|
| LINGO-1 antagonist | Promote OPC differentiation | Phase 2 |
| Clemastine | Promote remyelination | Phase 2 |
| Opicinumab (anti-LINGO-1) | Remyelination | Phase 2 |
| BHA | Antioxidant | Preclinical |
The study of Oligodendrocyte Dysfunction Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):37-53. PMID:19847447
Nave KA, Werner HB. Myelinization of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503-533. PMID:25288117
Michalski JP, Kothary R. Oligodendrocytes in a nutshell. Front Cell Neurosci. 2015;9:340. PMID:26441521
Simons M, Nave KA. Oligodendrocytes: myelination and axonal support. Cold Spring Harb Perspect Biol. 2015;8(1):a020479. PMID:26330520
Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487(7408):443-448. PMID:22801498
Philips T, Bento-Abreu A, Nonneman A, et al. Oligodendrocyte dysfunction in the pathogenesis of ALS. Brain. 2013;136(Pt 2):471-482. PMID:23348584
Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):616-630. PMID:22051941
Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging. 2004;25(1):5-18. PMID:14675724
Dean DC 3rd, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014;71(1):11-22. PMID:24240692
Braak H, Braak E. White matter lesions in the human brain: aging, Alzheimer's disease, and cerebrovascular disease. Ann N Y Acad Sci. 1997;826:384-388. PMID:9329707
Zhang J, Zhang Y, Wang J, et al. Characterizing white matter damage in Parkinson's disease with diffusion tensor MRI. Neurosci Lett. 2011;507(2):101-105. PMID:22192816
Sutherland GT, Lim J, Lumsden AL, et al. Subcortical white matter disease in Parkinson's with dementia. J Neurol Sci. 2015;358(1-2):277-283. PMID:26232113
Fancy SP, Kotter MR, Harrington EP, et al. Overcoming roadblocks in remyelination therapies. Ann Neurol. 2010;67(5):676-684. PMID:20437557
Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304-315. PMID:19334067
Piaton G, Aigrot MS, Williams A, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain. 2011;134(Pt 4):1156-1167. PMID:21354977
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 33% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 54%